P I Industries Ltd
P I Industries Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
From P I Industries Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves.
- Biologicals have been growing at double-digit rates and expected to continue as a key growth driver over next 5-10 years.
- Pharma business showed 54% Y-o-Y growth in H1 FY26; despite biotech funding slowdown, long-term positive outlook with capability building ongoing.
- AgChem exports experienced volume-led decline but new products grew 38% Y-o-Y in H1 FY26; 8-10 new molecules planned for commercialization this fiscal.
- Domestic business impacted by erratic rainfall and regulatory changes but expected positive trajectory in H2, especially with improved Rabi season outlook.
2 more points from P I Industries Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what P I Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth.
- In electronic chemicals, there are two dedicated plants: one near commissioning and another multi-product plant, indicating ongoing capex in this segment.
- Biologicals business is currently in the investment phase, including market and product development across the US, Brazil, Europe, Mexico, and India, along with commissioning a new biological research center in Hyderabad.
2 more points from P I Industries Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what P I Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current overall order book position stands at approximately $1.25 billion as of Q2 FY26.
- The company does not provide order book guidance broken down by specific fiscal years (e.g., FY26 or FY27).
- Demand normalization and inventory destocking in the global agrochemical industry are expected to improve order flow visibility from Q4 FY26.
- The management anticipates a recovery and positive growth trajectory in the second half of calendar year 2026.
2 more points from P I Industries Ltd's call on order book
Pro opens every point from 15K+ earnings calls
P I Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.6K Cr, net profit ₹200 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P I Industries Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Fertilizers & Agrochemicals this season
- Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
- Krishana Phosch. (Q2 FY26)
Trading contributes around 20%–22% of total turnover; trading volumes may vary depending on market conditions. Key concall takeaways from Krishana Phoschem…
- Sumitomo Chemi. (Q2 FY26)
Domestic sales grew 11% YoY in H1 FY '25-'26, with improved farmer connect initiatives like 'Every Day Farmers Day' enhancing demand. Key concall takeaways…
- Chambal Fertilisers & Chemicals Ltd (Q2 FY26)
Crop Protection and Speciality Nutrients show strong traction with a 28-29% year-on-year revenue growth and 37% growth in contribution margins; 22 new products…
Arthneeti Pro · Annual
P I Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were P I Industries Ltd Q2 FY26 results?
Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18).
What is P I Industries Ltd share price analysis?
P I Industries Ltd currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of ₹42,633 Cr. Investors should review the full earnings analysis for detailed insights.
Is P I Industries Ltd planning capital expenditure?
The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth.
Keep P I Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.